Eli Lilly’s tirzepatide shows promising results in MASH treatment study
Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide in treating metabolic dysfunction-associated steatohepatitis (MASH) with ... Read More
Takeda announces positive results for mezagitamab in Phase 2 ITP study
Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab ... Read More